Showing 2171-2180 of 3223 results for "".
- FDA Does Not Approve Bausch Health, Eton’s Pharma’s EM-100 for Allergic Conjunctivitishttps://modernod.com/news/fda-does-not-approve-bausch-health-etons-pharmas-em-100-for-allergic-conjunctivitis/2476731/Eton Pharmaceuticals on Friday said that partner Bausch Health Companies has received a complete response letter from the FDA for its filing seeking approval of the investigational therapy EM-100 to treat ocular itching associated with allergic conjunctivitis. “We
- Alcon Introduces Air Optix Plus HydraGlyde for Astigmatism Contact Lenseshttps://modernod.com/news/alcon-introduces-air-optix-plus-hydraglyde-for-astigmatism-contact-lenses/2479569/Alcon has launched Air Optix plus HydraGlyde for Astigmatism contact lenses in the United States. The newest addition to Alcon’s contact lens portfolio offers a combination of technologies that support long-lasting lens surface moisture and outstanding comfort to provide astigmatic patients a con
- EyeSouth Establishes Presence in Alabama Through Affiliation with Montgomery Eye Physicianshttps://modernod.com/news/eyesouth-establishes-presence-in-alabama-through-affiliation-with-montgomery-eye-physicians/2476711/EyeSouth Partners has announced that it has completed an affiliation with Montgomery Eye Physicians and Prescription Eyewear. The affiliation will be EyeSouth’s first in Alabama. Terms of the deal were not disclosed. EyeSouth is an eye care-focused management services organization.
- Promedica International and Dr. Agarwal’s Eye Hospitals Form Strategic Alliancehttps://modernod.com/news/promedica-international-and-dr-agarwals-eye-hospitals-form-strategic-alliance-2/2476709/Promedica International (PMI) and Dr. Agarwal’s Eye Hospitals (AEH) have formed a new partnership to conduct clinical trials in India. PMI and AEH stated that the alliance will enable them to collaboratively enroll and manage clinical studies in an expanded patient population, while conforming wi
- Alcon Launches New Dailies Colors Contact Lenseshttps://modernod.com/news/alcon-launches-new-dailies-colors-contact-lenses/2476702/Alcon officially announced the launch of new Dailies Colors contact lenses—daily disposable contact lenses that combine eye color enhancement with the convenience of a daily wear, according to a company news release. The new line features four colors—Mystic Blue, Mystic Gray, Mystic Hazel and Mys
- AlpineInvestors to Make Strategic Growth Investments in Ohio Eye Care Businesseshttps://modernod.com/news/alpineinvestors-to-make-strategic-growth-investments-in-ohio-eye-care-businesses/2476694/Private equity firm Alpine Investors has invested in Ohio-based eye care business, Northeast Ohio Eye Surgeons (NEOES), including its subsidiary business, Ohio Eye Care Consultants (OECC). The two companies will together form a new ophthalmology platform for Alpine, and will continue to operate i
- Alan R. Morse, JD, PhD, Vision and Healthcare Services Innovator, Will Retire As President & CEO of Lighthouse Guildhttps://modernod.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/James M. Dubin, Chairman of the Board of Lighthouse Guild, announced that Alan R. Morse, JD, PhD, will be stepping down later this year as President & CEO of Lighthouse Guild after an extraordinary career of almost 52 years as a leader and innovator in the field
- Aldeyra Therapeutics Phase 3 SOLACE Trial Fails to Meet Primary Endpoint in Noninfectious Anterior Uveitishttps://modernod.com/news/aldeyra-therapeutics-phase-3-solace-trial-fails-to-meet-primary-endpoint-in-noninfectious-anterior-uveitis/2476691/Aldeyra Therapeutics announced results from the noninfectious anterior uveitis SOLACE trial. Statistical significance was not achieved for the primary or secondary endpoints, due to high rates of disease resolution in vehicle-treated patients, but activity of reproxalap was consistently greater t
- AbbVie to Buy Allergan in Deal Worth $63 Billionhttps://modernod.com/news/abbvie-to-buy-allergan-in-deal-worth-63-billion/2476686/A blockbuster merger of two large pharma companies will have an impact on the eye care market as AbbVie announced its plans to buy Allergan in a deal worth $63 billion. Under the agreed terms, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share they h
- Generic Drug Maker Alembic Pharmaceuticals Receives FDA Approval for Bromfenac Ophthalmic Solution 0.09%https://modernod.com/news/generic-drug-maker-alembic-pharmaceuticals-receives-fda-approval-for-bromfenac-ophthalmic-solution-0-09/2476685/India-based Alembic Pharmaceuticals announced that the company has received FDA approval for its abbreviated new drug application (NDA) for bromfenac ophthalmic solution 0.09% for the treatment of postoperative inflammation and pain. The approved NDA is therapeutically equivalent to the re